Second Sight Medical Products (NASDAQ:EYES) stock rises above the 50-day moving average of $2.09
Shares of Second Sight Medical Products, Inc. (NASDAQ:EYES – Get Rating) rose above its 50-day moving average during Tuesday’s trading. The stock has a 50-day moving average of $2.09 and is trading down to $2.17. Shares of Second Sight Medical Products last traded at $2.16, with volume at 96,657 shares.
Analysts set new price targets
Separately, StockNews.com upgraded Second Sight Medical Products to a “sell” rating in a Wednesday, March 30 research note.
Second Sight Medical Product Price Performance
The company has a 50-day moving average of $2.09 and a 200-day moving average of $1.65.
Insider Buying and Selling at Second Sight Medical Products
In a similar vein, director Gregg Williams acquired 387,044 shares of Second Sight Medical Products in a trade on Wednesday, May 18. The shares were purchased at an average cost of $1.66 per share, with a total value of $642,493.04. Following the purchase, the director now directly owns 10,277,853 shares of the company, valued at $17,061,235.98. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available on the SEC’s website. Insiders purchased a total of 636,734 shares of the company worth $1,163,387 over the past ninety days. Insiders hold 47.20% of the shares of the company.
Hedge funds weigh on Second Sight medical products
A hedge fund recently bought a new stake in the shares of Second Sight Medical Products. Renaissance Technologies LLC bought a new position in shares of Second Sight Medical Products, Inc. (NASDAQ:EYES – Get Rating) in the first quarter, according to its most recent Form 13F filed with the Securities and Exchange Commission. The institutional investor bought 174,226 shares of the medical device company, valued at around $249,000. Renaissance Technologies LLC owned approximately 0.44% of Second Sight Medical Products at the end of the last quarter. 9.09% of the shares are currently held by institutional investors.
About Second Sight medical products
(Get an evaluation)
Second Sight Medical Products, Inc. develops, manufactures and markets implantable vision prostheses intended to provide artificial vision to people who are blind. It develops technologies to treat the population of visually impaired people. The Company offers the Orion Visual Cortical Prosthesis System, an implanted cortical stimulation device, intended to provide useful artificial vision to people who are blind due to a variety of causes, including glaucoma, diabetic retinopathy, optic nerve damage or disease, and eye damage.
Receive daily news and reviews for Second Sight medical products – Enter your email address below to receive a concise daily summary of breaking news and analyst ratings for Second Sight Medical Products and related companies with MarketBeat.com’s FREE daily newsletter.